Long-Term Safety and Efficacy of the Novel Β3 -Adrenoreceptor Agonist Vibegron in Japanese Patients With Overactive Bladder: A Phase III Prospective Study

International Journal of Urology - United Kingdom
doi 10.1111/iju.13596
Full Text
Abstract

Available in full text

Categories
Urology
Date
Authors
Publisher

Wiley

Related search

Editorial Comment From Dr Chapple to Long-Term Safety and Efficacy of the Novel Β3-Adrenoreceptor Agonist Vibegron in Japanese Patients With Overactive Bladder: A Phase III Prospective Study

International Journal of Urology
Urology
2018English

Mirabegron &Ndash; A Selective &Szlig;3-Adrenoreceptor Agonist for the Treatment of Overactive Bladder

Research and Reports in Urology
Urology
2012English

Solifenacin in Multiple Sclerosis Patients With Overactive Bladder: A Prospective Study

Advances in Urology
GynecologyUrologyObstetrics
2011English

Discovery of Vibegron: A Potent and Selective 3 Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

English

Efficacy and Safety of Botulinum Neurotoxin in Geriatric Patients With an Overactive Bladder: A Multicentric Study From Turkey

Turk Geriatri Dergisi
GerontologyGeriatrics
2019English

Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Gel in Japanese Patients With Psoriasis Vulgaris: A Phase III Study

Journal of the Japan Organization of Clinical Dermatologists
2018English

Long‐term Efficacy and Safety of Bexarotene for Japanese Patients With Cutaneous T‐cell Lymphoma: The Results of a Phase 2 Study (B‐1201)

Journal of Dermatology
DermatologyMedicine
2019English

The Efficacy and Safety of Uractiv Control in Overactive Bladder Treatment

Revista de Chimie
SurfacesMaterials ScienceEngineeringMaterials ChemistryFilmsCoatingsChemistry
2020English

OA08.01 Long-Term Efficacy and Safety of Nivolumab in Second- Or Third-Line Japanese Malignant Pleural Mesothelioma Patients (Phase II: MERIT Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy